Study details
Enrolling now
Evaluation Of Semaglutide in Adults With Cocaine Use Disorder With and Without HIV
University of Maryland, Baltimore
NCT IDNCT06691243ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
40
Study length
about 1.6 years
Ages
18–65
Locations
2 sites in DC, MD
About this study
This trial is testing whether semaglutide is safe and well-tolerated in adults with cocaine use disorder, both with and without HIV. Participants will receive either semaglutide or a placebo for 601 days.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Placebo
- 2.Take Semaglutide
PhasePhase 2
DrugSemaglutide
Routeoral
Primary goalTolerability of semaglutide in patients with cocaine use disorder (CUD) with and without HIV
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low10%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
semaglutide (GLP-1 agonist; stimulates insulin release)
Drug routes
oral (Oral Tablet)
Endpoints
Primary: Tolerability of semaglutide in patients with cocaine use disorder (CUD) with and without HIV
Body systems
Immune, Infectious